---
figid: PMC9357610__JCMM-26-4548-g005
pmcid: PMC9357610
image_filename: JCMM-26-4548-g005.jpg
figure_link: /pmc/articles/PMC9357610/figure/jcmm17478-fig-0001/
number: FIGURE 1
figure_title: ''
caption: 'Pirfenidone attenuated cardiac dysfunction induced by TAC in mice. (A) Representative
  echocardiographic graphs. (B–G) Echocardiographic analysis 8 weeks after TAC (n = 6).
  (H, I) Gross morphology of mouse heart and HW/BW ratio. Scale bar = 5 mm. (J, K)
  Representative H&E staining images and cross‐sectional area (CSA) of cardiomyocytes.
  Scale bar = 5μm. (L–N) Western blotting and relative expression of ANP and BNP in
  the indicated mice. *p < 0.05, ** p < 0.01 vs. Sham group; #p < 0.05, ##p < 0.01
  vs. TAC group'
article_title: Pirfenidone alleviates cardiac fibrosis induced by pressure overload
  via inhibiting TGF‐β1/Smad3 signalling pathway.
citation: Na Li, et al. J Cell Mol Med. 2022 Aug;26(16):4548-4555.
year: '2022'

doi: 10.1111/jcmm.17478
journal_title: Journal of Cellular and Molecular Medicine
journal_nlm_ta: J Cell Mol Med
publisher_name: John Wiley and Sons Inc.

keywords:
- cardiac fibrosis
- cardiac remodelling
- pirfenidone
- pressure overload
- transforming growth factor‐β1

---
